TherapeuticsMD Inc. (TXMD)
TXMD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K/A (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/25743/000121390026037918/0001213900-26-037918-index.htm. Net income: SEC 10-K/A (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TXMD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000025743 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.0M |
| Net income | -$569K |
| Operating income | -$4.4M |
| Net margin | -18.8% |
| Operating margin | -145.3% |
| Revenue growth | +71.6% |
| Cash | $7.5M |
| Total assets | $37.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements." | 10-Q 2026-11-13 |
| Cash and burn | $9.2M cash; operating cash flow $774K a quarter. | Report 2026-06-30 |
| Shares outstanding | 11,574,362 (2026-11-09); 11,574,362 a year earlier; 10,575,240 three years earlier. | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Carr, Riggs & Ingram LLC, Palm Beach Gardens, Florida, United States; changed auditors 1 time in 24 months | 8-K 4.01 2026-01-21 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-04-01 |
| Insider trades, 12 months | Bought $14K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $869K | $155K | $779K | $9.2M | No debt tags | $3.3M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $724K | $95K | $944K | $8.4M | No debt tags | $3.4M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $893K | -$619K | $375K | $7.5M | No debt tags | $3.0M | 10-K/A 2026-04-01 |
| Q3 2025 2025-09-30 | $784K | $152K | $999K | $7.1M | No debt tags | $2.8M | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $952K | $551K | $381K | $6.1M | No debt tags | $2.6M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $393K | -$653K | $699K | $5.7M | No debt tags | $1.8M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $667K | $252K | $17K | $5.1M | No debt tags | $1.8M | 10-K/A 2026-04-01 |
| Q3 2024 2024-09-30 | $547K | -$609K | -$71K | $5.0M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2022-03-24 |
| Latest annual report ANNUAL REPORT | 10-K/A | 2026-04-01 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-13 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-13 |
| Latest proxy PROXY STATEMENT | DEFA14A | 2025-11-03 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.5% |
| 1 month | -4.6% |
| 3 months | -10.1% |
| Year to date | +14.7% |
| 1 year | +15.4% |
| From 52-week high | -32.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CPHI | China Pharma Holdings Inc. | $0.4800 | -7.35% | $20.7M |
| IGC | IGC Pharma Inc. | $0.1750 | -0.57% | $20.4M |
| SHPH | Shuttle Pharmaceuticals Holdings Inc. | $4.24 | -6.40% | $20.2M |
| CELU | Celularity Inc. | $0.6191 | -1.75% | $20.1M |
| AYTU | Aytu BioPharma Inc. | $1.82 | +1.68% | $19.8M |
| ATOS | Atossa Therapeutics Inc. | $1.93 | -1.53% | $19.3M |
| RNAZ | TransCode Therapeutics Inc. | $1.35 | -1.46% | $22.9M |
| COCP | Cocrystal Pharma Inc. | $0.9777 | -0.24% | $18.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier